Chatham Rock to sell Avenir Makatea for $1.4M (Aust.)

On November 12, 2025, Chatham Rock Phosphate (CRP) announced it has signed a non-binding framework agreement to sell its subsidiary, Avenir Makatea Pty Ltd, to Austure Pty Ltd. The consideration for the sale is AUD 900,000 in cash, payable over a 24-month period, and a 20% shareholding in a dicalcium phosphate (DCP) and monocalcium phosphate (MCP) manufacturing plant to be developed by the purchaser. The agreement is conditional upon the signing of a definitive agreement by the end of December 2025.

This news is materially positive, primarily because it provides a desperately needed non-dilutive source of capital for a company with a precarious financial position. However, its non-binding nature is a significant risk that cannot be overlooked.

A chronological review of the company's announcements reveals a pattern of ambitious plans hampered by a severe lack of funding: - The Failed Korella Sale: In January 2025, CRP announced a proposed sale of its Korella projects for AUD 4.1M in cash plus a substantial royalty stream. This would have been transformative. However, by April 2025, the due diligence period was extended and the buyer had moved to a non-exclusive process, signaling the deal was collapsing. This failure is a critical piece of context, highlighting the execution risk on new deals. - Pivot to RailPhos: Following the collapse of the Korella sale, the company pivoted its narrative to the large-scale "RailPhos" project, a feasibility study for a railway to the Port of Karumba to enable bulk exports. This is a multi-hundred-million-dollar infrastructure project, an entirely unrealistic ambition for a company with less than CAD $50k in the bank and a market cap under $10M. The frequent "progress updates" on this project throughout mid-2025 appear to be attempts to maintain market interest without tangible, funded progress. - Constant Dilution: The company survives by conducting frequent, small, and increasingly dilutive private placements. Financings were done at $0.08 in late 2024, $0.07 in early 2025, and $0.05 more recently. More concerning is the company's inability to fill these small financings, raising only $112k of a planned $350k in March 2025, and $138k of a planned $175k in July 2025. This demonstrates extremely weak market support. - Dire Financials: The audited annual financial statements as of March 31, 2025, showed a cash balance of just CAD $35,206 and a working capital deficit of CAD $295,394. The company's net loss for the year was $1.18M. It is insolvent without continuous capital injections.

Within this context, the proposed sale of the Makatea asset for AUD 900,000 (approx. CAD $810,000) is a significant positive. While much smaller than the failed Korella deal, it provides a potential lifeline. The cash, even spread over 24 months, would cover a substantial portion of the company's G&A burn rate and reduce the immediate need for further value-destroying financings. The 20% stake in a future DCP/MCP plant also aligns with their stated strategy (Oct 22, 2025 news) and offers speculative upside.

The primary risk is that this is merely a non-binding framework. Given the failure of the previous asset sale, there is a high probability this deal also fails to close. If it does not become a definitive agreement by year-end, the company's dire financial situation will return to the forefront. Therefore, while the news is positive in its intent and potential impact, it is far from a certainty.

Chatham Rock Phosphate is a junior exploration and development company focused on phosphate. It holds a portfolio of geographically diverse projects: - Korella North & South (Queensland, Australia): These onshore phosphate projects are the company's current operational focus. Korella North is presented as a near-term production asset, aiming for both domestic sales and export. The company has also initiated the highly ambitious "RailPhos" project, a feasibility study to build a private railway to the Port of Karumba to facilitate bulk exports from the region. - Chatham Rise (New Zealand): A large, offshore marine phosphate project. Its advancement has been stalled for years due to the failure to obtain an environmental consent. While a new "Fast-track" approvals bill passed in late 2024 offers a renewed path forward, the re-application process will be lengthy and costly, and success is not guaranteed. - Makatea (French Polynesia): An onshore phosphate project which is the subject of the most recent news regarding its proposed sale.

The company's strategy appears to be monetizing non-core assets (Makatea) to fund the development of its Australian projects, particularly Korella North.